Title : Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.

Pub. Date : 2010 Apr

PMID : 20095796






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: In a phase 3 randomized, multicenter, double-blind, placebo-controlled study, first-line therapy with lapatinib plus paclitaxel significantly improved clinical outcomes based on a pre-planned analysis of ErbB2+ metastatic breast cancer patients (GSK Study #EGF30001; ClinicalTrials.gov identifier: NCT00075270). Paclitaxel erb-b2 receptor tyrosine kinase 2 Homo sapiens